The Vanderbilt Therapeutics Clinical Research Site a group of caring professionals working together to make a positive contribution in our fight against AIDS through the study of new ways to treat and prevent the disease.
This group has been operating since 1992 and is currently funded by the National Institutes of Health and pharmaceutical industry partners.
David Haas, M.D., is the principal investigator for this group of clinical trials and is responsible for overall conduct and coordination of the program.
Patients may gain access to new treatments not yet available to the general public.
Patients receive expert study-related medical care from Vanderbilt University's Infectious Diseases specialists.
What about confidentiality?
Our team is very sensitive to the privacy concerns of participants and take great care to make sure records are protected. In all study records a numerical code (patient identifier or "PID") is assigned to each participant. Actual names do not appear on the study records. The patient roster, which connects a name to a PID, is kept in a secured confidential binder.
How is participant safety protected?
All clinical trials are reviewed by the Food and Drug Aministration (FDA) and by Vanderbilt's Institutional Review Board (IRB). IRBs are independent committees whose job is to make sure participants' rights are fully protected and that volunteers are not exposed to any unnecessary risks.